Kilian E Salerno1, Baris Turkbey2, Liza Lindenberg2, Esther Mena2, Erica E Schott1, Alexandra K Brennan1, Soumyajit Roy3, Uma Shankavaram1, Krishnan Patel1, Theresa Cooley-Zgela1, Yolanda McKinney2, Bradford J Wood4, Peter A Pinto5, Peter Choyke2, Deborah E Citrin6. 1. Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD. 2. Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD. 3. Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD; Department of Radiation Oncology, Rush University Medical Center, Chicago, IL. 4. Center for Interventional Oncology, NIH Clinical Center, National Institutes of Health, Bethesda, MD. 5. Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD. 6. Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD. Electronic address: citrind@mail.nih.gov.
Abstract
PURPOSE/OBJECTIVE(S): This study describes the pattern of failure in patients with biochemical (BCR) recurrence after low-dose-rate (LDR) brachytherapy as a component of definitive treatment for prostate cancer. METHODS: Patients with BCR after LDR brachytherapy ± external beam radiation therapy (EBRT) were enrolled on prospective IRB approved advanced imaging protocols. Patients underwent 3T multiparametric MRI (mpMRI); a subset underwent prostate specific membrane antigen (PSMA)-based PET/CT. Pathologic confirmation was obtained unless contraindicated. RESULTS: Between January 2011 and April 2021, 51 patients with BCR after brachytherapy (n = 36) or brachytherapy + EBRT (n = 15) underwent mpMRI and were included in this analysis. Of 38 patients with available dosimetry, only two had D90<90%. The prostate and seminal vesicles were a site of failure in 66.7% (n = 34) and 39.2% (n = 20), respectively. PET/CT (n = 32 patients) more often identified lesions pelvic lymph nodes (50%; n = 16) and distant metastases (18.8%; n = 6), than mpMRI. Isolated nodal disease (9.8%; n = 5) and distant metastases (n = 1) without local recurrence were uncommon. Recurrence within the prostate was located in the transition zone in 48.5%, central or midline in 45.5%, and anterior in 36.4% of patients. CONCLUSION: In this cohort of patients with BCR after LDR brachytherapy ± EBRT, the predominant recurrence pattern was local (prostate ± seminal vesicles) with frequent occurrence in the anterior prostate and transition zone. mpMRI and PSMA PET/CT provided complementary information to localize sites of recurrence, with PSMA PET/CT often confirming mpMRI findings and identifying occult nodal or distant metastases. Published by Elsevier Inc.
PURPOSE/OBJECTIVE(S): This study describes the pattern of failure in patients with biochemical (BCR) recurrence after low-dose-rate (LDR) brachytherapy as a component of definitive treatment for prostate cancer. METHODS: Patients with BCR after LDR brachytherapy ± external beam radiation therapy (EBRT) were enrolled on prospective IRB approved advanced imaging protocols. Patients underwent 3T multiparametric MRI (mpMRI); a subset underwent prostate specific membrane antigen (PSMA)-based PET/CT. Pathologic confirmation was obtained unless contraindicated. RESULTS: Between January 2011 and April 2021, 51 patients with BCR after brachytherapy (n = 36) or brachytherapy + EBRT (n = 15) underwent mpMRI and were included in this analysis. Of 38 patients with available dosimetry, only two had D90<90%. The prostate and seminal vesicles were a site of failure in 66.7% (n = 34) and 39.2% (n = 20), respectively. PET/CT (n = 32 patients) more often identified lesions pelvic lymph nodes (50%; n = 16) and distant metastases (18.8%; n = 6), than mpMRI. Isolated nodal disease (9.8%; n = 5) and distant metastases (n = 1) without local recurrence were uncommon. Recurrence within the prostate was located in the transition zone in 48.5%, central or midline in 45.5%, and anterior in 36.4% of patients. CONCLUSION: In this cohort of patients with BCR after LDR brachytherapy ± EBRT, the predominant recurrence pattern was local (prostate ± seminal vesicles) with frequent occurrence in the anterior prostate and transition zone. mpMRI and PSMA PET/CT provided complementary information to localize sites of recurrence, with PSMA PET/CT often confirming mpMRI findings and identifying occult nodal or distant metastases. Published by Elsevier Inc.
Authors: Luca F Valle; Matthew D Greer; Joanna H Shih; Tristan Barrett; Yan Mee Law; Andrew B Rosenkrantz; Haytham Shebel; Akhil Muthigi; Daniel Su; Maria J Merino; Bradford J Wood; Peter A Pinto; Andra V Krauze; Aradhana Kaushal; Peter L Choyke; Barış Türkbey; Deborah E Citrin Journal: Diagn Interv Radiol Date: 2018 Jan-Feb Impact factor: 2.630
Authors: Mack Roach; Gerald Hanks; Howard Thames; Paul Schellhammer; William U Shipley; Gerald H Sokol; Howard Sandler Journal: Int J Radiat Oncol Biol Phys Date: 2006-07-15 Impact factor: 7.038
Authors: Nelson N Stone; Louis Potters; Brian J Davis; Jay P Ciezki; Michael J Zelefsky; Mack Roach; Katsuto Shinohara; Paul A Fearn; Michael W Kattan; Richard G Stock Journal: Int J Radiat Oncol Biol Phys Date: 2008-07-01 Impact factor: 7.038
Authors: Daniel E Spratt; Payal D Soni; Patrick W McLaughlin; Gregory S Merrick; Richard G Stock; John C Blasko; Michael J Zelefsky Journal: Brachytherapy Date: 2016-10-19 Impact factor: 2.362
Authors: Jeffrey A Kittel; Chandana A Reddy; Kristin L Smith; Kevin L Stephans; Rahul D Tendulkar; James Ulchaker; Kenneth Angermeier; Steven Campbell; Andrew Stephenson; Eric A Klein; D Allan Wilkinson; Jay P Ciezki Journal: Int J Radiat Oncol Biol Phys Date: 2015-05-08 Impact factor: 7.038
Authors: A Joshi; M J Roberts; M Perera; E Williams; H Rhee; D Pryor; M Lehman; P Heathcote; S Wood; J Coucher; S Gustafson; K Miles; I Vela Journal: Clin Exp Metastasis Date: 2020-06-09 Impact factor: 5.150
Authors: David M Routman; Ryan K Funk; Bradley J Stish; Lance A Mynderse; Torrence M Wilson; Robert McLaren; W Scott Harmsen; Kristin Mara; Christopher L Deufel; Keith M Furutani; Michael G Haddock; Thomas M Pisansky; C Richard Choo; Brian J Davis Journal: Brachytherapy Date: 2018-10-04 Impact factor: 2.362
Authors: Kenneth J Pienta; Michael A Gorin; Steven P Rowe; Peter R Carroll; Frédéric Pouliot; Stephan Probst; Lawrence Saperstein; Mark A Preston; Ajjai S Alva; Akash Patnaik; Jeremy C Durack; Nancy Stambler; Tess Lin; Jessica Jensen; Vivien Wong; Barry A Siegel; Michael J Morris Journal: J Urol Date: 2021-02-26 Impact factor: 7.450